The world top 5 best-selling drugs in 2020

News

The world top 5 best-selling drugs in 2020, 3 of which will exceed tens of billions of dollars

The world top 5 best-selling drugs in 2020.

Recently, major pharmaceutical companies have successively announced their 2020 financial reports.

Despite the impact of the epidemic, the results are not bad from the results of the financial reports.

The global sales of three drugs exceeded 10 billion US dollars at the same time, including AbbVie’s Humira , Merck’s Keytruda and Bristol-Myers Squibb’s Revlimid.

It is worth mentioning that these three drugs also ranked in the top three in 2019. However, compared with 2019, these three drugs all have different degrees of increase in 2020, of which Keytruda has a maximum increase of 29.74%.

According to the financial reports and public information of each company, Shell Club sorted out the top 5 drugs in sales in 2020 as follows, hoping to help everyone.

The world top 5 best-selling drugs in 2020.

01 Product name: Humira

Company: AbbVie, Eisai
2019/2020 sales (100 million US dollars): 191.69/198.32, a year-on-year increase of 3.46%

Humira was approved by the FDA in 2002 for the treatment of moderate to severe forms of rheumatoid arthritis, as a monotherapy or in combination with MTX or other disease-improving anti-rheumatic drugs. It is the world’s first fully human monoclonal antibody .

Since 2012, Humira has won the world’s No. 1 sales of prescription drugs for 9 consecutive years. According to statistics, Humira’s cumulative sales have exceeded 170 billion US dollars.

Up to now, Humira has been approved for use in adults with moderate to severe chronic rheumatoid arthritis and children with polyarticular juvenile idiopathic arthritis, psoriasis and psoriatic arthritis, ankylosing spondylitis, and children And adult Crohn’s disease, ulcerative colitis (only in the US and EU), etc.

In addition, Humira is conducting clinical trials for the treatment of sarcoidosis and uveitis. Humira has also been approved for rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis in China for 3 indications.

However, Humira will lose patent protection in the United States in 2023, which may have a certain impact on its sales.

02 Commodity name: Keytruda

Company: Merck
2019/2020 sales (100 million US dollars): 110.84/143.80, a year-on-year increase of 29.74%

Keytruda was approved by the FDA in 2017 for the treatment of microsatellite unstable solid tumors.

Keytruda is a fully human monoclonal antibody against PD-1 receptor, which can block PD-1 of T lymphocytes and block its interaction with The PD-L1 combination on the surface of tumor cells relieves the immune suppression of tumor cells on immune cells, so that immune cells can re-play the anti-tumor cell immunity and kill tumor cells.

In July 2018, Merck’s PD-1 monoclonal antibody Keytruda (Pembrolizumab) was approved by the National Medical Products Administration to be officially marketed in China.

It is used for locally advanced or metastatic melanoma that has progressed after first-line treatment.

The second PD-1/PD-L1 monoclonal antibody drug marketed in China after Opdivo. Although it was launched in China later than Opdivo, Keytruda has left Opdivo far behind with its wide range of indications.

As of now, Keytruda has obtained non-small cell lung cancer (China), small cell lung cancer, liver cancer, kidney cancer, stomach cancer, cervical cancer, endometrial cancer, esophageal cancer, melanoma , head and neck squamous cell carcinoma, Hodge Gold lymphoma, urothelial carcinoma, primary mediastinal large B-cell lymphoma, MSI-H solid tumor, Merck cell carcinoma, TMB-H solid tumor, skin squamous cell carcinoma, MSI-H/dMMR colorectal cancer More than 25 indications, including triple-negative breast cancer, have become veritable anti-cancer “magic drugs”.

According to GlobalData’s forecast, Keytruda will surpass Humira as the world’s best-selling drug in 2025, with sales reaching US$22.2 billion.

03 Commodity name: Revlimid

Company: Bristol-Myers Squibb
2019/2020 sales (100 million US dollars): 108.23/121.06, a year-on-year increase of 11.85%

Revlimid was approved by the FDA in 2006 for the treatment of multiple myeloma (MM).

It can block interleukin (IL)-6, IL-1β and tumor necrosis factor α (TNFα), which are found in MM cells. It plays an important role in the proliferation, growth, drug resistance, and angiogenesis.

Revlimid is a small molecule compound with anti-tumor activity. It is currently clinically mainly used to treat multiple myeloma, mantle cell lymphoma and myelodysplastic syndromes with 5q deletion.

Revlimid is a domestic first-line drug for the treatment of multiple myeloma, which can effectively inhibit the further spread and metastasis of cancer.

It is reported that in 2019, Bristol-Myers Squibb acquired Revlimid through the large-scale acquisition of Xinji. It is estimated that the sales of the drug will exceed 12.4 billion US dollars in 2025.

04 Commodity name: Imbruvica

Company: Johnson & Johnson, AbbVie
2019/2020 sales (100 million US dollars): 80.85/94.42, a year-on-year increase of 16.78%

The active ingredient of Imbruvica is ibrutinib, which is a pioneering BTK inhibitor that can block the signal pathway that mediates the uncontrolled proliferation and spread of B cells, help kill and reduce the number of cancer cells, and delay the progression of cancer.

In clinical studies, ibrutinib has been used as a single agent and combination therapy for a wide range of hematological malignancies and has shown strong efficacy.

Since it was first approved for marketing in 2013, Imbruvica has been approved for 5 types of B-cell blood cancers including mantle cell lymphoma, marginal zone lymphoma, small cell lymphoma, CLL, and WM, as well as chronic graft-versus-host disease.

There are as many as 10 therapeutic indications in 6 disease fields. Imbruvica was approved by the National Medical Products Administration in 2017 and can be used as a single drug for the treatment of CLL/SLL patients and MCL patients who have received at least one treatment in the past.

05 Commodity name: Eliquis

Company: Bristol-Myers Squibb, Pfizer
2019/2020 sales (100 million US dollars): 79.29/91.68, a year-on-year increase of 15.63%

Eliquis was approved by the FDA in 2012 to reduce the risk of non-valvular atrial fibrillation (atrial fibrillation) in patients with stroke and systemic embolism.

Eliquis is a direct inhibitor of oral coagulation factor Xa, which has high selectivity for coagulation factor Xa, and the binding is reversible.

It can produce antithrombotic effect without the effect of antithrombin III.

At present, in addition to the United States, Europe, Canada and Japan, Eliquis has been officially approved for the prevention of atrial fibrillation stroke and systemic embolism in 45 countries and regions including South Korea, Taiwan, Hong Kong, India, Malaysia, the Philippines and Singapore.

In addition, cardiovascular and cerebrovascular diseases are the world’s leading cause of death. some countries’s deaths due to cardiovascular and cerebrovascular diseases account for 45% of the total deaths. The number of deaths due to cardiovascular and cerebrovascular diseases is 2.6 million every year, an average of 340 deaths per hour.

The world top 5 best-selling drugs in 2020, 3 of which will exceed tens of billions of dollars

(source:internet, reference only)

Disclaimer of medicaltrend.org